Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab
{{output}}
Background: Treatment options in progressive glioblastoma (GBM) are limited, especially in patients who have experienced disease progression while receiving bevacizumab therapy. This phase 2 study was conducted to evaluate the ef... ...
